Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by alloreactive donor T-cell-mediated graft-versus-host disease (GvHD). The major polyphenol of green tea, epigallocatechin-3-gallate (EGCG), is an inhibitor of both DNA methyltransferase 1 (DNMT1) and signal transducer and activator of transcription 1 (STAT1), which are essential for induction of GvHD. Thus, in this report, we examine if in vivo administration of EGCG mitigates GvHD in several different animal models. While we concede that refinement of EGCG treatment might result in GvHD prevention, our results suggest that EGCG treatment might not be an effective therapy against GvHD in the clinic.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022695PMC
http://dx.doi.org/10.3727/096368913X667691DOI Listing

Publication Analysis

Top Keywords

graft-versus-host disease
8
egcg treatment
8
gvhd
5
epigallocatechin-3-gallate graft-versus-host
4
disease allogeneic
4
allogeneic hematopoietic
4
hematopoietic stem
4
stem cell
4
cell transplantation
4
transplantation allo-hsct
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!